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Summary Background A Phase I study to determine the
maximum tolerated dose (MTD) and pharmacokinetics of
afatinib (BIBW 2992), a novel irreversible ErbB Family
Blocker, administered orally once daily in a 3-week-on/1-
week-off dosing schedule. Methods Patients with advanced
solid tumors received single-agent afatinib at 10, 20, 40, 55
or 65 mg/day. Safety, antitumor activity, pharmacokinetics
and pharmacodynamic modulation of biomarkers were
assessed. Results: Forty-three patients were enrolled. Dose-
limiting toxicities (DLTs) occurred in five patients in the
dose escalation phase (1/8 at 40 mg/day; 1/6 at 55 mg/day;
3/6 at 65 mg/day). The MTD was established at 55 mg/day.
In the expansion cohort at the MTD, 6 patients experienced
a DLT in the first 28-day treatment period. The most fre-
quent DLT was diarrhea. The most common adverse events
were diarrhea, rash, nausea, vomiting and fatigue. Overall,
the afatinib safety profile in a 3-week-on/1-week-off dose
schedule was similar to that of our daily-continuous schedule.
Afatinib displayed dose-dependent pharmacokinetics at doses
up to and including 55 mg/day, with a terminal half-life
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suitable for once-daily dosing. Signs of clinical antitumor
activity were observed. In biopsies taken from clinically
normal forearm skin, afatinib caused a reduced prolifera-
tion rate, with a concomitant increase in differentiation of
epidermal keratinocytes. Conclusion Afatinib in a 3-
week-on/1-week-off schedule showed a good safety pro-
file. The MTD was 55 mg/day, although excess DLTs in
the expansion cohort indicated that the 40 mg/day dose
would have an acceptable safety profile for future studies.
Dose cohorts between 40 and 55 mg/day were not exam-
ined in this study.
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Introduction
The ErbB Family receptor tyrosine kinases (TK) include the
epidermal growth factor receptor (EGFR; ErbB1), the hu-
man epidermal growth factor receptor (HER2; ErbB2),
ErbB3 and ErbB4 [1, 2]. EGFR and HER2 are important
therapeutic targets [3] but resistance to both EGFR- and
HER2-targeted therapies is frequently observed [4, 5]. Irre-
versible inhibition of receptor TKs, or inhibition of multiple
receptors in the ErbB Family, may help to prevent or over-
come resistant disease as observed in the clinic.
Afatinib is a novel, potent, small molecule ErbB Family
Blocker that covalently binds and irreversibly blocks sig-
naling through activated EGFR, HER2 and ErbB4 receptors,
as well as the transphosphorylation of ErbB3 [6, 7]. Afatinib
is thought to inhibit cancer-relevant ErbB Family dimers,
regardless of receptor dimerization status. Irreversible bind-
ing possibly improves inhibition of tumor cell proliferation
compared with reversible TK inhibitors (TKIs). In vitro
studies have demonstrated that afatinib has superior activity
to gefitinib and erlotinib in cells expressing EGFR-
activating mutations, and superior in vivo antitumor activity
in animal models compared with gefitinib and erlotinib [6].
In trastuzumab-resistant HER2-overexpressing breast and
gastric cancer cell lines, as well as xenograft models [8],
afatinib demonstrated antitumor activity. Results of Phase II
studies in HER2-positive, trastuzumab-resistant patients
with breast cancer were also encouraging [9].
This study was one of four Phase I studies conducted
as part of the afatinib Phase I program to explore differ-
ent dosing schedules of afatinib monotherapy in patients
with solid tumors. This open-label dose-escalation study
evaluated once-daily treatment with afatinib in a 3-week-
on/1-week-off dose schedule in patients with advanced
solid tumors. The primary objective was to determine the
maximum tolerated dose (MTD) of afatinib. The pharma-
cokinetics (PK) and antitumor activity of afatinib were
also evaluated, along with an assessment of afatinib’s
pharmacodynamic modulation of biomarkers.
Patients and methods
Study design
This study was conducted in line with the Declaration of
Helsinki (1996 version), the International Conference on
Harmonization Tripartite Guidelines for Good Clinical Prac-
tice and local legislation, and was approved by all review
boards at the individual participating sites. The starting dose
was 10 mg/day afatinib and tablets were to be taken at the
same time each morning under fasting conditions. Dose
escalation was performed in cohorts of three patients and
subsequently amended to yield six evaluable patients from
every cohort from 20–55 mg. If no dose-limiting toxicity
(DLT) occurred during the first 28-day treatment period,
doses were doubled in each new cohort until NCI Common
Terminology Criteria for Adverse Events (CTCAE version
3.0) Grade ≥2 occurred in ≥1 patient/cohort. Thereafter,
escalation steps of no greater than 35 % were allowed. The
maximum tolerated dose (MTD) was defined as the dose of
afatinib at which no more than one out of six patients
experienced a DLT. Once the MTD was determined, the
MTD cohort was expanded to a total of 18 evaluable
patients to further evaluate safety and antitumor activity. A
treatment cycle was defined as a 28-day period (3 weeks on
afatinib followed by 1 week off [3-week-on/1-week-off]).
After 6 treatment cycles, patients were entered into an
extension study.
Eligibility
Male or female patients, aged ≥18 years, with confirmed
advanced, non-resectable and/or metastatic solid tumors
known to express EGFR and/or HER2, and not respon-
sive to established treatments, were enrolled. Patients
had to have a life expectancy of ≥3 months; an Eastern
Cooperative Oncology Group (ECOG) performance
score of 0–2; resolution of prior treatment-related ad-
verse events (AEs) to Grade ≤1; recovery from surgery;
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patients recruited at the MTD level were required to have
measurable lesions. Exclusion criteria included compromised
hematological, renal and liver function; active infectious dis-
ease; chronic diarrhea or gastrointestinal disorders; left ven-
tricular ejection fraction (LVEF) CTC Grade ≥1; untreated or
symptomatic brain metastases; and treatment with other in-
vestigational, EGFR- or HER2-inhibiting drugs within
4 weeks (8 weeks for trastuzumab).
Safety and tolerability assessments
All AEs were graded according to CTCAE version 3.0.
DLTs were defined as the following AEs, if they oc-
curred within the first 28-day treatment cycle: Grade 4
hematologic AEs; Grade 3 or 4 non-hematologic AEs
(except untreated nausea, vomiting, or diarrhea); AEs of
Grade ≥2 for LVEF or renal function; and persistent
Grade ≥2 nausea and/or vomiting for ≥7 days despite
optimal supportive care.
Antitumor activity and pharmacodynamic assessments
Objective tumor responses were evaluated according to
Response Evaluation Criteria in Solid Tumors [RECIST
1.0] every 8 weeks from start of treatment. Pharmacody-
namics, i.e., the modulation of expression of EGFR-
associated biomarkers, including EGFR, phosphorylated
mitogen-activated protein kinase (p-MAPK), phosphorylat-
ed Akt (pAkt) [10], Ki-67 (an indicator of cellular prolifer-
ation); and p27KIP1 (kinase inhibitory protein 1) were
assessed by immunohistochemistry on skin punch biopsies
(4 mm width×4 mm depth) taken from the lateral aspect of
the upper extremity, and tumor biopsies. Skin punch and
tumor samples for pharmacodynamic assessment were taken
just before the first dose of afatinib, and on Day 21 of the
first treatment cycle. Skin biopsies were taken on Day 21 of
the 3-week-on/1-week-off treatment regimen as it was an-
ticipated that pharmacodynamic effects would be maximal
or more pronounced at this time point, based on results from
an earlier study where biopsies had been taken at 2 weeks in
a 2-week-on/2-week-off regimen [11]. Specimens were im-
mediately fixed in 10 % buffered neutral formalin for 16–
24 h, and embedded in paraffin. Treatment effects of afatinib
were assessed by counting ≥1000 epidermal keratinocytes
and scoring those positively stained for Ki-67 and p27KIP1.
The number of Ki-67 and p27KIP1 positive keratinocytes
was expressed as a percentage of the total keratinocytes
observed. The expression of pMAPK, pAkt and EGFR in
epidermal keratinocytes was assessed as for Ki-67 and
p27KIP1, with the percentage of pMAPK-, pAkt- and
EGFR-positive keratinocytes expressed as a percentage of
the total keratinocytes counted. In addition, the intensity of
pMAPK, pAkt and EGFR staining was estimated using the
Allred scoring system [12]. Paired t-tests were performed
for both Ki-67 and p27KIP1.
PK sampling and data analysis
Blood samples (5 mL) for PK were collected prior to dosing
and 0.5, 1, 2, 3, 4, 5, 7, 9 and 24 h after afatinib adminis-
tration on Days 1 and at Day 21 of Cycle 1. Additionally, a
PK sample was taken at 48 and 72 h after drug administra-
tion on Day 21 of Cycle 1. Additional trough PK samples
were collected on Days 8 and 15 of Cycle 1. In patients
receiving additional cycles, trough PK samples were col-
lected on Days 8, 15 and 22 of each cycle. PK sample
collection and analysis were performed according to previ-
ously published methods [11].
Non-compartmental analysis was conducted using Win-
Nonlin® (Version 4.1, Pharsight, Mountainview, CA, USA).
Standard non-compartmental methods were used to calcu-
late the following PK parameters at steady-state: the area
under the plasma concentration versus time curve from 0 to
24 h at steady state (AUC0–24,ss), peak plasma concentration
at steady state (Cmax,ss), the apparent total body clearance
after extravascular administration at steady state (CL/Fss),
the apparent volume of distribution after extravascular ad-
ministration at steady state (VZ/Fss), the terminal half-life at
steady state (t½,ss) and the accumulation ratio of Cmax and
AUC values at Days 1 and 21 (RA,Cmax and RA,AUC). Time
to peak plasma concentration at steady state (tmax,ss) was
reported as a median value.
Results
Patient disposition and exposure
Forty-three patients accrued from two study sites received
afatinib. The first patient was enrolled in March 2004, and
the last patient completed the follow-up visit in February
2006. Approximately two-thirds of patients were female,
the mean age (male and female) was 61 years, and the
majority of patients had received ≥3 lines of prior therapy
(Table 1).
A total of 65 % of patients received more than one
treatment cycle, and 16 % completed six cycles (Table 2).
Four out of seven patients who completed six cycles were
rolled over into an afatinib extension study.
DLTs and MTD
DLTs occurred in one patient in the dose escalation phase, and
in six patients in the expansion cohort at the MTD (Table 2).
All DLTs were Grade 3 in severity apart from the renal failure
reported in the 55 mg/day group, which was Grade 2. No
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DLTs occurred at 10 or 20 mg/day. At 40 mg/day, a 66-year-
old female patient with colorectal cancer (CRC) developed a
Grade 3 rash lasting 13 days, which resolved after dose
reduction. In the 55 mg/day cohort, one patient developed a
Grade 3 stomatitis. In the 65 mg/day cohort, three of the six
patients experienced DLTs: diarrhea in one patient; dehydra-
tion and fatigue in another patient; and diarrhea, nausea,
vomiting and dehydration in a further patient. Hence, the
55 mg/day dose was established as the MTD and was further
evaluated in an expansion cohort, in which 14 patients, rather
than the planned 12 patients, were treated. Of them, six
patients developed DLTs including diarrhea (three patients),
mucosal inflammation (one patient), dermatitis acneiform
(one patient), and anorexia, dehydration and renal failure
(one patient). Overall, seven of 20 patients treated at the
MTD 55mg/day developed an AE qualifying as a DLT during
the first cycle, thus exceeding the preset limit in the protocol.
Further enrolment into this dose cohort was discontinued. An
expansion cohort below 55 mg/day was not evaluated.
Safety and tolerability
Overall, afatinib was tolerated with mainly mild or moderate
(Grade 1 and 2) AEs. No Grade 4 or 5 AEs were observed.
Table 3 summarizes all treatment-related AEs observed in
the first 28-day cycle and in subsequent treatment cycles by
dose level and CTCAE grade.
Drug-related AEs were experienced by a total of 40
patients (93.0 %) during the course of the trial (38
within their first 28-day cycle). The most frequently
reported drug-related AEs during the conduct of the
entire trial included diarrhea (n=28 [65.1 %]), rash
(n=25 [58.1 %]), nausea (n=18 [41.9 %]), vomiting
(n=15 [34.9 %]), fatigue (n=9 [20.9 %]), anorexia
(n=7 [16.3 %]), epistaxis and mucosal inflammation
(n=10 [23.3 %] each), and stomatitis (11 [25.6 %]).
No treatment-related Grade ≥2 AEs were observed in
the 10 mg afatinib dose cohort. In patients who received
afatinib at a dose of 40 mg/day, Grade 2 or 3 AEs
included rash and nausea in two patients each, and
folliculitis, dehydration, diarrhea, vomiting, dysuria,
fatigue and mucosal inflammation in one patient each.
There appeared to be a dose relationship for incidence
and intensity of diarrhea. At dose levels below the
MTD, only one patient experienced Grade 2 diarrhea.
At the MTD, Grade 2 and 3 diarrhea occurred in
20 % and 25 % of patients. While no drug-related
diarrhea was observed at 10 mg and 20 mg afatinib
doses, 50 % of the patients developed diarrhea at
40 mg, 90 % at 55 mg, and the incidence increased
to 100 % at 65 mg/day. No diarrhea episode was
reported after the first 28-day cycle. In the majority
of cases (80 %), diarrhea started within 1–7 days after
afatinib treatment initiation. Only one patient treated
below the MTD discontinued due to diarrhea; this
patient received 40 mg.
Skin disorders were relatively mild at all dose levels
(mostly Grade 1 or 2). There were single skin-related
adverse events of Grade 3 in the 10–40 mg/day dose
group and at the 55 mg/day dose level, respectively. In
the majority of cases, skin events began 7–28 days after
treatment initiation. Skin events were considered to be
related to afatinib in most cases (91 %).
Fifteen patients (34.9 %) experienced a serious adverse
event (SAE). The most common SAE was treatment-related
diarrhea (six patients) in the 55 mg/day and 65 mg/day dose
cohorts. Three deaths occurred during afatinib administra-
tion (one of unknown cause, one of myocardial infarction
and one of progressive breast cancer). None were consid-
ered to be related to afatinib.
No patients had Grade ≥2 reductions in LVEF. Grade 3
aspartate aminotransferase elevations were only observed
after discontinuation of the trial drug and associated with
progression of disease in three patients with known liver
metastases for CRC and breast cancer (BC).
Antitumor activity
There were no confirmed objective responses; however, some
signs of antitumor activity were reported in this largely
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heavily pretreated cancer population. One patient with squa-
mous-cell skin carcinoma experienced a transient partial re-
sponse with a decrease in tumor size of 31 %, but showed
progressive disease at the repeat evaluation 2 months later.
One patient with parotid carcinoma had tumor shrinkage of
13 % in Cycle 4, which was maintained until Cycle 6. This
patient was then enrolled into an extension study and received
treatment for a total of 322 days. Two more patients, one with
non-small cell lung cancer (NSCLC) and one with CRC,
showed a decrease in tumor size of 27 % and 14 %, respec-
tively. In addition, 8 patients had stable disease for at least
16 weeks and received at least 5 cycles of treatment.
Pharmacodynamics
A total of 29 paired skin samples (i.e., 29 pretreatment and
29 on-therapy skin specimens obtained from the clinically
normal forearm skin of the patient) were available for phar-
macodynamic studies. At doses of ≥ 55 mg/day, treatment
with afatinib significantly reduced the number of Ki-67-
positive cells in skin biopsies by 31 %, demonstrating inhi-
bition of epidermal keratinocyte cell proliferation (Fig. 1a
and b). This was accompanied by an increase in the total
number of p27KIP1-positive epidermal keratinocytes, which
was about 16 % higher than pretreatment samples (Fig. 1c
and d). A similar trend was observed at lower doses. No
significant changes were observed in levels of pMAPK and
EGFR in normal skin punch biopsies between pretreatment
and on-therapy samples. While no significant difference in
the level of pAkt was observed between the pretreatment
and on-therapy paired skin biopsies in eight out of 29 paired
samples, there was a slight decrease in pAkt staining and in
nine out of 29 cases a slight increase. In the 12 remaining
cases, no treatment-induced changes were observed. There-
fore, the observed changes were probably due to biological
inter- and intra-patient variability.
Pharmacokinetics
Geometric mean (gMean) plasma concentration–time curves
of afatinib are displayed in Fig. 2. Afatinib exhibited similar
disposition kinetics after single and multiple dosing, which
could be described by at least bi-exponential disposition
kinetics. The gMean plasma concentrations on Days 1 and
Table 2 Patient disposition and DLTs
Afatinib dose Total
10 mg/day 20 mg/day 40 mg/day 55 mg/day 65 mg/day
Patients treated, ntotal 3 6 8 20 6 43 (100.0)
Patients who completed 1 cycle, n (%) 0 (0.0) 1 (16.7) 4 (50.0) 7 (35.0) 3 (50.0) 15 (34.9)
Patients who completed 4 cycles, n (%) 1 (33.3) 1 (16.7) 0 (0.0) 2 (10.0) 0 (0.0) 4 (9.3)
Patients who completed 6 cycles, n (%) 0 (0.0) 1 (16.7) 2 (25.0) 3 (15.0) 1 (16.7) 7 (16.3)
Patients treated in extension study, n (%) – – – – – 4 (9.3)
DLTs occurring during the first
treatment cyclea
n (%) – – 1 (12.5) 7 (35.0) 3 (50.0) 11 (25.6)
Rash (1 pt) Stomatitis (1 pt) Diarrhea (1 pt)








renal failure (1 pt)
Discontinued due to:
DLT, n (%) – – – 3 (15.0) 1 (16.7) 4 (9.3)
Other toxicity, n (%) – – 1 (12.5) 4 (20.0) 2 (33.3) 7 (16.3)
Disease progression, n (%) 3 (100.0) 2 (33.3) 3 (37.5) 8 (40.0) 1 (16.7) 17 (39.5)
Consent withdrawn, n (%) – – – 1 (5.0) – 1 (2.3)
Other reasonsb, n (%) – 1 (16.7) 1 (12.5) 1 (5.0) 1 (16.7) 4 (9.3)
DLTs dose limiting toxicities, pt patient, CTC common terminology criteria
n = number of patients; ntotal = total number of patients in each group
% based on ntotal
a All DLTs listed were CTC Grade 3 except renal failure, which was CTC Grade 2
b Includes worsening of disease other than cancer, lost to follow-up, non-compliant and other
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21 increased with dose. Steady-state was reached within
8 days of once-daily dosing of afatinib, at the latest. At
steady-state, both maximum plasma concentrations (Cmax,ss)
and exposure (AUC0–24,ss), increased with the administered
dose (Table 4). Peak plasma concentrations at steady-state
were reached 3–5 h after dosing (median tmax,ss values). The
gMean terminal half-life at steady-state was measured over a
range between 35 and 43 h at Day 2. A moderate-to-high
apparent total body clearance and a high volume of distribu-
tion were determined for afatinib (Table 4). The gMean accu-
mulation ratios ranged from 1.36 to 2.35 when based on Cmax
values, and from 1.81 to 3.07 when based on AUC values.
Moderate-to-high inter-patient variability for all PK parame-
ters was detected over all groups.
Discussion
The MTD of afatinib administered in a 3-week-on/1-week-
off dose schedule was primarily determined to be 55 mg/
day. However, due to the much higher occurrence of diar-
rhea at the 55 mg/day compared with the 40 mg/day dose,
and the number of additional DLTs that were observed in the
expansion cohort, the recommended dose for further studies
using this schedule seems to be 40 mg/day, although dose
cohorts between 40 and 55 mg/day were not examined in
this study. Three other afatinib monotherapy Phase I studies
using alternative dosing schemes have been performed in
patients with solid tumors as part of the development pro-
gram for afatinib; one study used a 2-week-on/2-week-off
schedule [11], and two studies used a continuous dosing
schedule [13, 14]. Based on the combined results from these
four trials, 50 mg/day afatinib was established as the rec-
ommended Phase II dose for a continuous dosing schedule.
Afatinib was found to have an acceptable safety profile
with no treatment-related Grade ≥4 AEs reported in any of
the afatinib dose cohorts assessed in a 3-week-on/1-week-
off schedule. As reported in other Phase I studies conducted
with afatinib [11, 14], the most commonly reported
treatment-related AEs were diarrhea, rash and nausea and
were manageable with appropriate supportive care and dose
reduction.
The adverse-event profile reported with afatinib was
consistent with the safety profile of EGFR inhibitors
[15–20]. In a Phase I dose-escalation study of the EGFR
inhibitor gefitinib administered continuously in patients
with solid tumors, DLTs observed were rash and diarrhea.
The incidence of all grades of diarrhea appeared to be dose
related and predominantly began during the first treatment
period [18]. Incidence and severity of diarrhea also appeared
to be related to dose during a Phase I investigation of
erlotinib [19]; a pattern which was in agreement with results
in this Phase I trial. Diarrhea was experienced within 1–
7 days after starting afatinib treatment, with no
Table 3 Selected treatment-related AEs by treatment, highest CTCAE grade and preferred term
Adverse events, n
Afatinib dose (mg/day) 10 20 40 55 65
Gradea 1 1 2 1 2 3 1 2 3 1 2 3
Cycleb 1 ≥2 1 ≥2 1 ≥2 1 ≥2 1 ≥2 1 ≥2 1 ≥2 1 ≥2 1 ≥2 1 ≥2 1 ≥2 1 ≥2
Nausea 1 0 0 0 0 0 2 0 0 0 2 0 5 1 4 0 0 0 1 0 1 0 1 0
Vomiting 1 0 0 0 1 0 1 2 0 0 1 0 3 1 2 0 1 0 1 0 0 0 1 0
Stomatitis 0 0 2 0 0 0 1 0 0 0 0 0 2 2 1 0 1 0 2 0 0 0 0 0
Diarrhea 0 0 0 0 0 0 2 0 1 0 1 0 9 0 4 0 5 0 2 0 2 0 2 0
Pruritus 1 0 0 0 0 0 1 1 0 0 0 0 2 0 2 0 0 0 3 0 0 0 0 0
Rash 1 0 0 0 0 1 3 0 1 0 1 0 10 0 3 1 0 0 3 0 1 0 0 0
Dry skin 0 0 1 0 0 0 0 0 0 0 0 0 4 3 0 0 0 0 2 0 0 0 0 0
Dermatitis acneiform 0 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 1 0 0 0 0 0 0 0
Epistaxis 0 0 2 0 0 0 0 0 0 0 0 0 5 2 0 0 0 0 1 0 0 0 0 0
Anorexia 0 0 0 0 0 0 0 1 0 0 0 0 1 0 1 1 2 0 0 0 1 0 0 0
Dehydration 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 2 0 0 0 0 0 2 0
Fatigue 0 0 0 0 0 0 0 0 0 0 1 0 0 0 4 1 0 1 1 0 0 0 1 0
Mucosal inflammation 0 0 0 0 0 0 0 1 1 0 0 0 4 1 1 0 1 0 1 0 0 0 0 0
AEs adverse events, CTCAE Common Terminology Criteria for Adverse Events
a Worst CTCAE Grade
b The cycle in which AEs started; Cycle length: 28 days; No treatment-related Grade ≥2 AEs were observed in the 10 mg dose cohort. No
treatment-related Grade ≥4 AEs were reported in any of the afatinib dose cohorts.
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discontinuations at lower doses indicating that appropriate
management with early institution of supportive care and
timely dose reductions are crucial to keep patients on afati-
nib while they are benefiting from treatment.
In agreement with other studies [11, 14], afatinib was
absorbed moderately fast and displayed a terminal half-life
that favors a once-daily dosing schedule (Fig. 2; Table 4).
No deviation from dose linear PK was observed after a
single dose or at steady-state either in this study or in
studies using other dose ranges and schedules [11, 14].
A relatively high apparent total body clearance and
volume of distribution were observed. Since the abso-
lute bioavailability of afatinib in humans is unknown, these
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Fig. 2 Geometric mean drug
plasma concentration–time
profiles of afatinib after single
and multiple rising oral
administration of 10, 20, 40, 55
and 65 mg once daily afatinib
tablets for 21 days in Treatment
Period 1







































































Fig. 1 Ki-67 and p27KIP1 response in normal skin by dose. Afatinib
treatment (all doses) resulted in a reduction in the number of Ki-67-
positive epidermal keratinocytes expressed as a percentage of total kera-
tinocytes assessed (mean±SD; on-therapy versus pretreatment samples)
(a), and this reduction in the number of Ki-67-positive keratinocytes was
also observed after afatinib treatment regardless of dose for each
individual patient (each line represents results from a single patient) (b).
Afatinib treatment resulted in an increase in the number of p27KIP1-
positive keratinocytes expressed as a percentage of total keratinocytes
assessed (mean±SD) in pretreatment and on-therapy samples (c). Similar
effects were seen for the majority of individual patients (d)
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indicate that afatinib has a suitable elimination profile and a
high tissue distribution. All PK parameters displayed
moderate-to-high variability, although parameters were in
the expected range compared with other EGFR TKIs
[20–23]. Analysis of the correlations between the PK and
AE data in this population was not conducted because the
PK data were too sparse.
Biomarker analysis of skin biopsies showed no changes
in EGFR levels after 3 weeks of treatment with afatinib at
any dose. This observation in benign skin biopsies is not
necessarily unexpected and is similar to previous findings
[11]. Treatment with afatinib resulted in significant inhibi-
tion of epidermal keratinocyte proliferation as judged by the
Ki-67 index. This was accompanied by a significant in-
crease in the number of p27KIP1-positively stained epider-
mal keratinocytes, indicating an induction in differentiation
of the epidermal keratinocytes assessed. In preclinical mod-
els, an induction of cellular differentiation has been corre-
lated with the arrest of cellular growth associated with the
inhibition of the EGFR pathway [24]. While these data
indicate that treatment with afatinib results in modulation
of EGFR signaling pathways, there was no change in levels
of pMAPK, pAkt or EGFR. This observation may be due to:
(i) a lack of inhibitory effect of afatinib on downstream
EGFR effectors pAkt and pMAPK; ( ii) activation of
alternate rescue pathways (re)activating these downstream
effectors, or, (iii) methodological shortcomings including a
low detection threshold or selection of inappropriate time-
points to capture any conceived changes.
Although no confirmed responses were observed in this
trial of heavily pretreated patients, antitumor activity of
afatinib has been confirmed in multiple trials using afatinib
at 40 mg/day or 50 mg/day in a daily-continuous dosing
schedule. As a consequence, a continuous once-daily regi-
men is considered the optimal dosing for afatinib. This
schedule is currently being assessed in ongoing Phase III
trials in HER2-positive breast cancer, NSCLC, and head and
neck squamous-cell carcinoma. Results from a completed
Phase III trial in patients with advanced lung adenocarcino-
ma and EGFR mutations (LUX-Lung 3) have shown that
afatinib is associated with prolongation of progression-free
survival when compared with standard first-line doublet
therapy [25].
In conclusion, afatinib in a 3-week-on/1-week-off sched-
ule showed a tolerable safety profile. The MTD was defined
per protocol to be 55 mg/day. However, the excess DLTs
observed in the expansion cohort show that the 40 mg/day
dose would have an acceptable safety profile for future
studies. Dose cohorts between 40 and 55 mg/day were not
examined in this study.
Table 4 Geometric mean (and geometric coefficient of variation %) PK parameters of afatinib at steady-state (Day 21) after oral administration of
10 mg, 20 mg, 40 mg, 55 mg and 65 mg once daily afatinib tablets in Treatment Period 1
Afatinib dose, once daily
10 mg 20 mg 40 mg 55 mg 65 mg
No. of patients 3 6 5 11 2a
Cmax,ss (ng/mL) 3.99 (83.7) 31.3 (94.1) 58.9 (83.7) 90.8 (67.8)
b 18.0, 94.7
Cmax,ss,norm ([ng/mL]/mg) 0.399 (83.7) 1.57 (94.1) 1.47 (83.7) 1.65 (67.8)
b 0.277, 1.46
AUC0–24,ss (ng·h/mL) 63.7 (99.8) 455 (61.8) 908 (69.1) 1360 (68.1)
b 355, 1270
AUC0–24,ss,norm ([ng·h/mL]/mg) 6.37 (99.8) 22.8 (61.8) 22.7 (69.1) 24.7 (68.1)
b 5.46, 19.5
tmax,ss
c (h) 4.00 (0.533–4.07) 5.00 (0.500–9.08) 3.00 (0.467–7.08) 3.00 (2.00–5.00)b 9.00, 2.00
t½,ss (h) 35.7 (33.1) 43.2 (37.9) 42.8 (35.9) 35.1 (14.1) 33.3, 25.8
CL/Fss (mL/min) 2620 (99.8) 732 (61.8) 734 (69.1) 653 (6.53) 3050, 856
Vz/Fss (L) 8080 (76.6) 2740 (66.8) 2720 (70.1) 2040 (62.0)
b 8780, 1910
RA,Cmax 1.36 (88.9) 2.06 (31.1) 1.88 (55.0) 2.35 (53.9)
b 0.488, 1.15
RA,AUC 1.81 (50.5) 3.07 (34.0) 2.27 (39.6) 2.90 (42.0)
b 1.34, 1.50
PK pharmacokinetic, Cmax,ss maximum measured concentration of the analyte in plasma at steady-state, Cmax,ss,norm maximum measured
concentration of the analyte in plasma at steady-state (dose-normalized), tmax,ss time from dosing to the maximum concentration of the analyte
in plasma at steady-state, AUC0–24,ss area under the concentration–time curve of the analyte in plasma over the respective time interval (hours) at
steady-state; AUC0–24,ss,norm area under the concentration–time curve of the analyte in plasma over the respective time interval (hours) at steady-
state (dose-normalized), t½,ss terminal half-life of the analyte in plasma at steady-state, CL/Fss apparent clearance of the analyte in plasma following
extravascular administration at steady-state, Vz/Fss apparent volume of distribution during the terminal phase λz following an extravasular dose at
steady-state, RA,Cmax accumulation ratio of Cmax after multiple dose administration over a uniform dosing interval, RA,AUC accumulation ratio of
AUC after multiple dose administration over a uniform dosing interval
a Individual values are displayed
b n010
c Median and range are displayed
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